Gilead Archives -

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jyseleca (filgotinib) 200mg tablets to treat ulcerative

UK green lights Gilead Sciences, Galapagos ulcerative colitis drug

https://pharmaphorum.com/news/uk-green-lights-gilead-sciences-galapagos-ulcerative-colitis-drug/

Market Access/ News/ News

Gilead takes legal action against counterfeit HIV drug network

Eloise McLennan Biktarvy, counterfeit drugs, Descovy, Gilead, HIV 0 Comment

US pharma giant Gilead Sciences has accused a network of unauthorised suppliers and distributors of selling more than

Gilead takes legal action against counterfeit HIV drug network

https://pharmaphorum.com/news/gilead-takes-legal-action-against-counterfeit-hiv-drug-network/

News/ News/ Oncology

Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs

Phil Taylor Arcus Biosciences, Gilead, immuno-oncology, Oncology, partnering, R&D, TIGIT 0 Comment

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal

Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs

https://pharmaphorum.com/news/gilead-foregoes-buyout-but-pledges-725m-to-arcus-cancer-drugs/

Crowd of adult citizens walking on city street - New reality lifestyle concept with senior people with covered faces - Selective focus on bearded man with blue protective mask

Oncology/ Views & Analysis/ Views and analysis

Blood Cancer UK: Hopes for our community’s future in the time of COVID

Kate Keightley blood cancer, Blood Cancer UK, covid, Gilead, Kite, patients 0 Comment

This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness

Blood Cancer UK: Hopes for our community’s future in the time of COVID

https://pharmaphorum.com/oncology/blood-cancer-uk-hopes-for-our-communitys-future-in-the-time-of-covid/

Patients/ Views & Analysis/ Views and analysis

Addressing the HIV epidemic in Eastern Europe and Central Asia

mike.hammerton@pharmaphorum.com AIDS, asia, Eastern Europe, Elton John AIDS Foundation, Gilead, HIV, RADIAN 0 Comment

Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021

Addressing the HIV epidemic in Eastern Europe and Central Asia

https://pharmaphorum.com/patients/gilead-hiv-epidemic-eastern-europe-central-asia/

Close up view of a dedicated worker carrying a stack of duck taped brown boxes in factory storage room while wearing sterile cloths and rubber gloves.

Patients/ Views & Analysis/ Views and analysis

Improving access to treatments in challenging markets

Jessica Hagen access to medication, Gilead, remdesivir 0 Comment

The COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at

Improving access to treatments in challenging markets

https://pharmaphorum.com/patients/gilead-jirair-ratevosian-treatment-access/

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

Market Access/ Oncology/ R&D/ Views & Analysis/ Views and analysis

New Cell & Gene Therapy Collective seeks to boost UK adoption

George Underwood Astellas, bluebird bio, BMS, Cell & Gene Collective, cell and gene therapy, cell therapy, gene therapy, Gilead, Kite, Novartis, UK 0 Comment

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the

New Cell & Gene Therapy Collective seeks to boost UK adoption

https://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

Richard Staines Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology 0 Comment

In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

https://pharmaphorum.com/news/allogene-announces-pivotal-trial/

R&D/ Views & Analysis/ Views and analysis

Collaboration is key to advancing cell therapy research

mike.hammerton@pharmaphorum.com CAR T, cell therapy, Gilead, Kite 0 Comment

Dr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company

Collaboration is key to advancing cell therapy research

https://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/

Trending

Gilead

Login